Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.
By Fortunato Ciardiello, R. Caputo, R. Bianco, V. Damiano, G. Pomatico, S. Placido, A. Bianco, G. Tortora. Clinical Cancer Research, 2000
998 citations recorded by the source corpus.
View Paper: https://www.semanticscholar.org/paper/04b43b3565167f9fefebfd576f4c643d4024a7b4
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- Fortunato Ciardiello
- N. Hynes
- E. Wood
- A. Wakeling
- G. Tortora
- Thomas Holbro
- D. Longley
- L. Falzone
Citations in the corpus
- The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. (2001, background): “EGFR and ErbB-2 are known to signal through the Ras pathway, stimulating cell division (3), and through the PI3K pathway, resulting in cell growth and survival (1).”
- A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. (2001, background): “Finally, evidence of antitumor activity of OSI-774 in patients with advanced NSCLC that had failed a platinum-based therapy was reported recently (98).”
- The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. (2001, unknown): “cells is under clinical development (Ciardiello et al. 2000).”
- Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium (2018, background): “In preclinical studies, Gefitinib demonstrated antitumor activity in several human cancer cell lines over-expressing EGFR, including lung, ovarian, breast, and colon cancer cell lines (Ciardiello et al., 2000).”
- ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. (2002, background): “Other investigators have also noted that the level of expression of EGFR in cells or tumors did not predict sensitivity to ZD1839 (14, 23).”
- The EGF receptor family as targets for cancer therapy (2000, background): “ZD1839 also demonstrated antitumor activity in nude mice bearing human GEO colon cancer xenografts (Ciardiello et al., 2000).”
- ErbB receptors: directing key signaling networks throughout life. (2004, background): “In combination with cytotoxic drugs, the cytostatic effect of the compound is enhanced and apoptosis increased (107).”